DSDavid H. Stitelman

David H. Stitelman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David H. Stitelman has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Investigation of the protein corona and biodistribution profile of polymeric nanoparticles for intra-amniotic delivery

    by Anna Y. Lynn, Kwangsoo Shin, David A. Eaton, Micky Rose, Xianzhi Zhang, Madalina Ene, Julian Grundler, Emily Deschenes, Rachel Rivero, Laura G. Bracaglia, et al.


  • Open Access

    Biodistribution of Polymeric Nanoparticles following in utero Delivery to a Nonhuman Primate

    by David A Eaton, Anna Y Lynn, Juliana M Surprenant, Emily I Deschenes, Mary Elizabeth Guerra, Rachel Rivero, Nicholas K Yung, Merissa O'COnnor, Peter M Glazer, Mert Ozan Bahtiyar, et al.

    Introduction: Monogenic diseases can be diagnosed before birth. Systemic fetal administration of nanoparticles (NPs) grants therapeutic access to developing stem cell populations impacted by these classes of disease. Delivery of editing reagents in these NPs administered before birth has yielded encouraging results in preclinical mouse models of monogenic diseases. Methods: To translate this strategy clinically, the safety and efficacy of this strategy in larger animals will be necessary. We performed a pilot biodistribution study in 3 fetal nonhuman primates (NHPs) in mid-gestation examining systemic delivery of polymeric NPs loaded with fluorescent dye. Results: We found several similarities in distribution to our experience in mice, namely, extensive uptake in fetal liver and spleen. A striking finding that is not recapitulated in the mouse was the accumulation of NPs in the zones of proliferation and ossification of the fetal bone. Of great importance, there did not appear to be NP accumulation in the fetal male or female germline zones or maternal tissue. Conclusion: These studies were vital to the next step of testing editing reagents in the fetal NHP with a goal of treating monogenic diseases before birth.


  • Open Access

    Systemic in utero gene editing as a treatment for cystic fibrosis

    by Adele S. Ricciardi, Christina Barone, Rachael Putman, Elias Quijano, Anisha Gupta, Richard Nguyen, Hanna Mandl, Alexandra S. Piotrowski-Daspit, Francesc Lopez-Giraldez, Valerie Luks, et al.

    In utero gene editing has the potential to modify disease causing genes in multiple developing tissues before birth, possibly allowing for normal organ development, disease improvement, and conceivably, cure. In cystic fibrosis (CF), a disease that arises from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, there are signs of multiorgan disease affecting the function of the respiratory, gastrointestinal, and reproductive systems already present at birth. Thus, treating CF patients early is crucial for preventing or delaying irreversible organ damage. Here we demonstrate proof-of-concept of multiorgan mutation correction in CF using peptide nucleic acids (PNAs) encapsulated in polymeric nanoparticles and delivered systemically in utero. In utero editing was associated with sustained postnatal CFTR activity, at a level similar to that of wild-type mice, in both respiratory and gastrointestinal tissue, without detection of off-target mutations in partially homologous loci. This work suggests that systemic in utero gene editing represents a viable strategy for treating monogenic diseases before birth that impact multiple tissue types.


  • The Technical and Ethical Framework of Fetal Therapy: Past and Current Advances

    by Anna Y. Lynn, Peter M. Glazer, W. Mark Saltzman, David H. Stitelman

    Purpose of Review Fetal therapy, a burgeoning field that encompasses prenatal surgical and medical interventions for congenital diseases, enables minimally invasive strategies of pharmacologic drug treatment before birth. We provide an overview of fetal drug delivery, its connections to current clinical practices, and key aspects for the clinician and researcher developing these approaches. Recent Findings A growing number of preclinical and clinical studies have demonstrated the success of nanomedicine for fetal applications, which we present here. In addition, we discuss the feasibility of fetal drug delivery from technical and ethical standpoints. Summary Fetal drug delivery still has many areas that require further investigation to understand its full implications. This review provides insights into what is currently known about the feasibility of fetal drug delivery and highlights important ethical considerations as fetal drug delivery continues to improve and advance toward clinical translation.


  • Open Access

    In utero delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic hernia

    by Sarah J. Ullrich, Nicholas K. Yung, Tory J. Bauer-Pisani, Nathan L. Maassel, Mary Elizabeth Guerra, Mollie Freedman-Weiss, Samantha L. Ahle, Adele S. Ricciardi, Maor Sauler, W. Mark Saltzman, et al.


  • Cholecystitis and Gallstone Disease

    by Nathan Maassel, David H. Stitelman

  • Open Access

    Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells

    by Valerie L. Luks, Hanna Mandl, Jenna DiRito, Christina Barone, Mollie R. Freedman-Weiss, Adele S. Ricciardi, Gregory G. Tietjen, Marie E. Egan, W. Mark Saltzman, David H. Stitelman

    Background: Advances in Molecular Therapy have made gene editing through systemic or topical administration of reagents a feasible strategy to treat genetic diseases in a rational manner. Encapsulation of therapeutic agents in nanoparticles can improve intracellular delivery of therapeutic agents, provided that the nanoparticles are efficiently taken up within the target cells. In prior work we had established proof-of-principle that nanoparticles carrying gene editing reagents can mediate site-specific gene editing in fetal and adult animals in vivo that results in functional disease improvement in rodent models of β-thalassemia and cystic fibrosis. Modification of the surface of nanoparticles to include targeting molecules (e.g. antibodies) holds the promise of improving cellular uptake and specific cellular binding. Methods and findings: To improve particle uptake for diseases of the airway, like cystic fibrosis, our group tested the impact of nanoparticle surface modification with cell surface marker antibodies on uptake in human bronchial epithelial cells in vitro. Binding kinetics of antibodies (Podoplanin, Muc 1, Surfactant Protein C, and Intracellular Adhesion Molecule-1 (ICAM)) were determined to select appropriate antibodies for cellular targeting. The best target-specific antibody among those screened was ICAM antibody. Surface conjugation of nanoparticles with antibodies against ICAM improved cellular uptake in bronchial epithelial cells up to 24-fold. Conclusions: This is a first demonstration of improved nanoparticle uptake in epithelial cells using conjugation of target specific antibodies. Improved binding, uptake or specificity of particles delivered systemically or to the luminal surface of the airway would potentially improve efficacy, reduce the necessary dose and thus safety of administered therapeutic agents. Incremental improvement in the efficacy and safety of particle-based therapeutic strategies may allow genetic diseases such as cystic fibrosis to be cured on a fundamental genetic level before birth or shortly after birth.


  • Outcomes following adoption of a standardized protocol for abscess drain management in pediatric appendicitis

    by Lindsay M. Eysenbach, Michael G. Caty, Emily R. Christison-Lagay, Robert A. Cowles, Brian Dillon, Thomas Robin Goodman, Doruk E. Ozgediz, David H. Stitelman, Daniel G. Solomon


  • Minimally Invasive Fetal Therapy for Myelomeningocele

    by Mollie R. Freedman-Weiss, David H. Stitelman


  • Open Access

    In utero nanoparticle delivery for site-specific genome editing

    by Adele S. Ricciardi, Raman Bahal, James S. Farrelly, Elias Quijano, Anthony H. Bianchi, Valerie L. Luks, Rachael Putman, Francesc López-Giráldez, Süleyman Coşkun, Eric Song, et al.

    Genetic diseases can be diagnosed early during pregnancy, but many monogenic disorders continue to cause considerable neonatal and pediatric morbidity and mortality. Early intervention through intrauterine gene editing, however, could correct the genetic defect, potentially allowing for normal organ development, functional disease improvement, or cure. Here we demonstrate safe intravenous and intra-amniotic administration of polymeric nanoparticles to fetal mouse tissues at selected gestational ages with no effect on survival or postnatal growth. In utero introduction of nanoparticles containing peptide nucleic acids (PNAs) and donor DNAs corrects a disease-causing mutation in the β-globin gene in a mouse model of human β-thalassemia, yielding sustained postnatal elevation of blood hemoglobin levels into the normal range, reduced reticulocyte counts, reversal of splenomegaly, and improved survival, with no detected off-target mutations in partially homologous loci. This work may provide the basis for a safe and versatile method of fetal gene editing for human monogenic disorders.